[Use of angiotensin type II receptor blockers as a potential strategy for chronic heart failure].
Angiotensin II is one of the most important key molecules for cardiac remodeling and apoptosis, culminating in heart failure. Therefore, angiotensin II receptor blockers (ARBs) have been expected to improve the mortality and morbidity in patients with heart failure more effectively strict elimination of the effects of angiotensin II compared with angiotensin-converting-enzyme inhibitors (ACEI). Here, we summarize the current clinical outcomes obtained from large scale trials using ARBs as a strategy of the treatment of heart failure, and discuss the pharmacological differences between ARB and ACEI and the future direction of the treatment of heart failure.